Positioning Infliximab and Vedolizumab in the Treatment of Moderate-to-Severe Ulcerative Colitis
- PMID: 34864070
- DOI: 10.1053/j.gastro.2021.12.002
Positioning Infliximab and Vedolizumab in the Treatment of Moderate-to-Severe Ulcerative Colitis
Comment on
-
Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis.Clin Gastroenterol Hepatol. 2022 Jul;20(7):1588-1597.e3. doi: 10.1016/j.cgh.2021.07.038. Epub 2021 Jul 28. Clin Gastroenterol Hepatol. 2022. PMID: 34329776
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
